evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

31 questions · 31 findings · 4 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 10 · 32.3%GRADE not reported 0 · 0%Very low 9 · 29%Low 11 · 35.5%Moderate 1 · 3.2%High 0 · 0%

Ribavirin vs no ribavirin

All‐cause mortality · people diagnosed with suspected or confirmed Crimean Congo haemorrhagic fever

It is very uncertain whether ribavirin changes mortality compared with no ribavirin (very low certainty).

1 finding from 1 review

Ribavirin vs no ribavirin

Requirement for transfusion (platelets) · people diagnosed with suspected or confirmed Crimean Congo haemorrhagic fever

It is very uncertain whether ribavirin changes requirement for transfusion (platelets) compared with no ribavirin (very low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

Sustained virological response · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…

It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (very low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

Relapse · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…

It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes relapse compared with standard peginterferon plus ribavirin treatment (very low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

End of treatment response (ETR) · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…

It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (very low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

Sustained virological response · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin

Extended peginterferon plus ribavirin treatment for 72 weeks may leads to higher sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

Relapse · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin

Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower relapse rate compared with standard peginterferon plus ribavirin treatment (low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

End of treatment response (ETR) · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin

Extended peginterferon plus ribavirin treatment for 72 weeks may leads to lower end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (low certainty).

1 finding from 1 review

Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment

Adherance to treatment · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin or participants with detectable…

Extended peginterferon plus ribavirin treatment for 72 weeks probably leads to lower adherance to treatment compared with standard peginterferon plus ribavirin treatment (moderate certainty).

1 finding from 1 review

Peginterferon plus ribavirin vs non‐pegylated interferon plus ribavirin

All‐cause mortality or liver‐related morbidity · people with chronic hepatitis C

Peginterferon plus ribavirin showed no clear difference in liver‐related morbidity plus all‐cause mortality compared with non‐pegylated interferon plus ribavirin (low certainty).

1 finding from 1 review

Peginterferon plus ribavirin vs non‐pegylated interferon plus ribavirin

Discontinuation of medication due to adverse events · people with chronic hepatitis C

Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).

1 finding from 1 review

Peginterferon plus ribavirin vs non‐pegylated interferon plus ribavirin

Sustained virological response · people with chronic hepatitis C

It is very uncertain whether peginterferon plus ribavirin changes sustained virological response compared with non‐pegylated interferon plus ribavirin (very low certainty).

1 finding from 1 review

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

Sustained virological response · patients on HD with HCV infection

It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes sustained virological response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).

1 finding from 1 review

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

End‐of‐treatment response · patients on HD with HCV infection

It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes end‐of‐treatment response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).

1 finding from 1 review